TITLE

Metformin Best for Diabetic Patients With Heart Failure

PUB. DATE
October 2007
SOURCE
Clinician Reviews;Oct2007, Vol. 17 Issue 10, p14
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses research being done on antidiabetic agents for patients with heart failure. It references a study by Eurich D.T., McAlister F.A., Blackburn D.F., et al. in the 2007 issue of the "British Medical Journal". Metformin was confirmed to be the only antidiabetic agent, among insulin, sulfonylureas and thiazolidinediones, that has no side effect to patients with heart failure. Morbidity and mortality rates were studied from mid-July 2007 electronic databases, revealing metformin to have decreased risk of all-cause mortality by 14% to 30%.
ACCESSION #
27084371

 

Related Articles

  • Recovery Studies on Metformin Hydrochloride and Gliclazide Combined Dosage Form (Tablets) Using Rp-Hplc Techniques. Saha, Dibyajyoti; Paul, Swati // International Journal of Pharmacy Teaching & Practices (IJPTP);Dec2012, Vol. 3 Issue 4, p405 

    Metformin hydrochloride is 1, 1-dimethyl biguanide hydrochloride and is also a hypoglecaemic drug. Gliclazide, is a third generation sulphonyl urea class hypoglycaemic drug which acts via stimulating β- cells of the isleta of langerhans of pancreas to release insulin. Metformin HCL differs...

  • hypoglycaemic (Major drug group).  // Royal Society of Medicine: Medicines;2002, p292 

    The article presents information on hypoglycemic drugs. These drugs reduce the levels of glucose in the bloodstream. They are used mainly in the treatment of diabetes mellitus. The oral hypoglycemic drugs are primarily used to treat Type II diabetes mellitus, for example, the sulphonylurea...

  • Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia. Bodmer, Michael; Meier, Christian; Krahenbuhl, Stephan; Jick, Susan S.; Meier, Christoph R. // Diabetes Care;Nov2008, Vol. 31 Issue 11, p2086 

    OBJECTIVE -- Lactic acidosis has been associated with use of metformin. Hypoglycemia is a major concern using sulfonylureas. The aim of this study was to compare the risk of lactic acidosis and hypoglycemia among patients with type 2 diabetes using oral antidiabetes drugs. RESEARCH DESIGN AND...

  • Haemodynamic and Metabolic Effects of Low Daily Dose Sulphonylureas in Diabetic Dog Hearts. Posa, Ildiko; Kocsis, Erzsebet; Nieszner, Eva; Pogatsa, Gabor; Koltai, Maria Zsofia // Drug Research / Arzneimittel-Forschung (Editio Cantor Verlag fur;Jul2002, Vol. 52 Issue 7, p552 

    The effects of glibenclamide (GB, CAS 10238-21-8) and those of the latest low dally dose sulphonylurea compound, glimepiride (GM, CAS 93479-97-1) on myocardial haemodynamics and pyruvatelactate metabolism of healthy and alloxan-diabetic dogs (n = 6 in six groups) were compared. Mean arterial...

  • Metformin does not harm diabetic patients with heart failure.  // Journal of Family Practice;Dec2007, Vol. 56 Issue 12, p996 

    The article focuses on the risk of oral hypoglycemics to patients with diabetes and heart failure. It is stated that some evidence suggests the control of blood glucose to be associated with worse outcomes in patients with heart failure. It is noted that antidiabetic agents such as metformin may...

  • The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II Diabetic subjects. Yudkin, J. S.; Panahloo, A.; Stehouwer, C.; Emeis, J. J.; Bulmer, K.; Mohamed-Ali, V.; Denver, A. E. // Diabetologia;Sep2000, Vol. 43 Issue 9, p1099 

    Aims/hypothesis. Improved glycaemic control might reduce both microvascular and macrovascular complications of Type II diabetes (non-insulin-dependent) mellitus. To explore such possible mechanisms, we investigated the effects of intensive treatment on markers of endothelial dysfunction and of...

  • The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus. Rendell, Marc // Drugs;2004, Vol. 64 Issue 12, p1339 

    The sulphonylureas act by triggering insulin release from the pancreatic β cell. A specific site on the adenosine triphosphate (ATP)-sensitive potassium channels is occupied by sulphonylureas leading to closure of the potassium channels and subsequent opening of calcium channels. This results...

  • Reduced second phase insulin secretion in carriers of a sulphonylurea receptor gene variant associating with Type II diabetes mellitus. ’t Hart, L. M.; Dekker, J. M.; van Haeften, T. W.; Ruige, J. B.; Stehouwer, C. D. A.; Erkelens, D. W.; Heine, R. J.; Maassen, J. A. // Diabetologia;Apr2000, Vol. 43 Issue 4, p515 

    Aims/hypothesis. The sulphonylurea receptor is a subunit of the ATP-sensitive potassium channel in the pancreatic beta cell. Mutations at nt –3 of the splice acceptor site of exon 16 and a silent mutation in exon 18 of the gene for the sulphonylurea receptor (SUR1) associate with Type II...

  • Triple Therapy with Rosiglitazone (RSG) or Insulin (INS) and Associated Medical Resource Use (MRU) and Costs in Type 2 Diabetes (T2D). Palmer, Liisa; Baser, Onur; Arondekar, Bhakti; Horblyuk, Ruslan // Diabetes;Jun2007 Supplement 1, Vol. 56, pA650 

    Clinical trials have demonstrated that intensive therapy to control blood glucose levels results in lower rates of complications and can substantially reduce the economic burden of T2D. Historically, T2D therapy has been based on a stepwise approach. When patients fail to achieve a therapeutic...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics